KNSA Valuation

Kiniksa Pharmaceuticals International PLC

Add to Watchlist

Advanced Chart

27.040

+0.71(2.697%)1D

Overview
Forecast
Valuation
Earnings

KNSA Relative Valuation

KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KNSA is overvalued; if below, it's undervalued.

Historical Valuation

Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.10 is considered Undervalued compared with the five-year average of -291.95. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between 34.51 to 39.80 according to relative valuation methord. Compared to the current price of 26.93 USD , Kiniksa Pharmaceuticals International PLC is Undervalued By 21.97%.

Relative Value

Fair Zone

34.51-39.80

Current Price：26.93

21.97%

Undervalued

24.34

Trailing

Forward

22.38

EV/EBITDA

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBITDA of 22.38. The 5-year average EV/EBITDA is -28.43. The thresholds are as follows: Strongly Undervalued below -327.71, Undervalued between -327.71 and -178.07, Fairly Valued between 121.21 and -178.07, Overvalued between 121.21 and 270.85, and Strongly Overvalued above 270.85. The current Forward EV/EBITDA of 22.38 falls within the Historic Trend Line -Fairly Valued range.

21.42

EV/EBIT

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBIT of 21.42. The 5-year average EV/EBIT is -0.62. The thresholds are as follows: Strongly Undervalued below -77.41, Undervalued between -77.41 and -39.01, Fairly Valued between 37.78 and -39.01, Overvalued between 37.78 and 76.17, and Strongly Overvalued above 76.17. The current Forward EV/EBIT of 21.42 falls within the Historic Trend Line -Fairly Valued range.

3.03

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current PS of 3.03. The 5-year average PS is 21.42. The thresholds are as follows: Strongly Undervalued below -100.47, Undervalued between -100.47 and -39.52, Fairly Valued between 82.37 and -39.52, Overvalued between 82.37 and 143.31, and Strongly Overvalued above 143.31. The current Forward PS of 3.03 falls within the Historic Trend Line -Fairly Valued range.

30.14

P/OCF

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/OCF of 30.14. The 5-year average P/OCF is -24.15. The thresholds are as follows: Strongly Undervalued below -387.69, Undervalued between -387.69 and -205.92, Fairly Valued between 157.62 and -205.92, Overvalued between 157.62 and 339.39, and Strongly Overvalued above 339.39. The current Forward P/OCF of 30.14 falls within the Historic Trend Line -Fairly Valued range.

14.01

P/FCF

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/FCF of 14.01. The 5-year average P/FCF is -37.93. The thresholds are as follows: Strongly Undervalued below -360.98, Undervalued between -360.98 and -199.46, Fairly Valued between 123.60 and -199.46, Overvalued between 123.60 and 285.13, and Strongly Overvalued above 285.13. The current Forward P/FCF of 14.01 falls within the Historic Trend Line -Fairly Valued range.

Kiniksa Pharmaceuticals International PLC (KNSA) has a current Price-to-Book (P/B) ratio of 4.19. Compared to its 3-year average P/B ratio of 3.26 , the current P/B ratio is approximately 28.54% higher. Relative to its 5-year average P/B ratio of 3.54, the current P/B ratio is about 18.28% higher. Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward Free Cash Flow (FCF) yield of approximately 2.23%. Compared to its 3-year average FCF yield of 0.73%, the current FCF yield is approximately 203.43% lower. Relative to its 5-year average FCF yield of -5.48% , the current FCF yield is about -140.68% lower.

4.19

P/B

Median3y

3.26

Median5y

3.54

2.28

FCF Yield

Median3y

0.73

Median5y

-5.48

Competitors Valuation Multiple

The average P/S ratio for KNSA's competitors is 8.14, providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of 3.03, which is -62.73% above the industry average. Given its robust revenue growth of 72.54%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

KNSA.O

Kiniksa Pharmaceuticals International PLC

Ocular Therapeutix Inc

Supernus Pharmaceuticals Inc

Amicus Therapeutics Inc

Performance Decomposition

Market capitalization of KNSA increased by 1.65% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 79.86M to 137.79M.

The secondary factor is the P/E Change, contributed 57.08%to the performance.

Overall, the performance of KNSA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

72.54%

79.86M → 137.79M

Revenue Growth

-127.97%

-22.17 → 6.20

Margin Expansion

57.08%

-71.13 → -111.73

P/E Change

1.65%